{"prompt": "['investigating perioperative nivolumab in at least T2 disease with two doses given prior to', 'nephrectomy and 9 months of therapy following surgery [33]. Pembrolizumab itself has been', 'applied in the neoadjuvant setting in bladder cancer but not yet RCC. Necchi, et al. recently', 'published data investigating the use of pembrolizumab in the neoadjuvant setting in patients with', 'muscle-invasive bladder carcinoma. Fifty patients received 3 cycles of pembrolizumab prior to', 'radical cystectomy (RC). 23 patients achieved a complete pathologic response (42%) at the time', 'of RC and 27 patients (54%) who had a PD-L1 combined positive score of > 10% achieved the', 'same [34].', 'Taken together, there is ample data to support the use of immunotherapy in the management of', 'mRCC and the combination of immunotherapy and targeted therapy has recently begun and', 'represents a promising new approach by attacking two mechanisms of tumorigenesis', 'simultaneously: immunosuppression and angiogenesis. However, this combination has yet to be', 'applied in the neoadjuvant setting and there remains gaps in our knowledge of how to best', 'approach the management of patients with locally advanced RCC. We have phase Ib/II data on', 'the combination of pembrolizumab and lenvatinib in the mRCC with promising response rates', 'and manageable adverse events. Thus, we propose the novel application of this combination in', 'the neoadjuvant setting for locally advanced RCC.', '4.2.2 Justification for Dose', 'The planned dose of lenvatinib for this study is 20 mg daily. In the phase 1b/II trial of these two', 'therapeutics together in selected metastatic solid tumors including RCC, patients received one of', 'three lenvatinib dose levels including 24 mg, 20 mg and 14 mg daily. The maximum tolerated', 'dose was determined to be 20 mg daily in combination with pembrolizumab [26]. This is the', 'dose of lenvatinib applied in the currently enrolling phase III CLEAR triple-arm trial which', 'examines the efficacy of lenvatinib 20 mg daily plus pembrolizumab versus lenvatinib 18 mg', 'daily plus everolimus versus sunitinib in metastatic RCC [27].', 'The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on', 'the totality of data generated in the Keytruda development program, 200 mg Q3W is the', 'appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.', 'As outlined below, this dose is justified by:', 'Clinical data from 8 randomized studies demonstrating flat dose- and exposure-efficacure-efficacy', 'relationships from 2 mg/kg Q3W to 10 mg/kg every 2 weeks (Q2W),', 'Clinical data showing meaningful improvement in benefit-risk including overall survival', 'at 200 mg Q3W across multiple indications, and', 'Pharmacology data showing full target saturation in both systemic circulation (inferred', 'from pharmacokinetic [PK] data) and tumor (inferred from physiologically-based PK', '[PBPK] analysis) at 200 mg Q3W', 'Among the 8 randomized dose-comparison studies, a total of 2262 participants were enrolled', 'with melanoma and non-small cell lung cancer (NSCLC), covering different disease settings', 'Page 8', 'Version Date: 05/08/2020']['(treatment na\u00efve, previously treated, PD-L1 enriched, and all-comers) and different treatment', 'settings (monotherapy and in combination with chemotherapy). Five studies compared 2 mg/kg', 'Q3W versus 10 mg/kg Q2W (KN001 Cohort B2, KN001 Cohort D, KN002, KN010, and', 'KN021), and 3 studies compared 10 mg/kg Q3W versus 10 mg/kg Q2W (KN001 Cohort B3,', 'KN001 Cohort F2 and KN006). All of these studies demonstrated flat dose- and exposure-', 'response relationships across the doses studied representing an approximate 5- to 7.5-fold', 'difference in exposure. The 2 mg/kg (or 200 mg fixed-dose) Q3W provided similar responses to', 'the highest doses studied. Subsequently, flat dose-exposure-response relationships were also', 'observed in other tumor types including head and neck cancer, bladder cancer, gastric cancer and', 'classical Hodgkin Lymphoma, confirming 200 mg Q3W as the appropriate dose independent of', 'the tumor type. These findings are consistent with the mechanism of action of pembrolizumab,', 'which acts by interaction with immune cells, and not via direct binding to cancer cells.', 'Additionally, pharmacology data clearly show target saturation at 200 mg Q3W. First, PK data', 'in KN001 evaluating target-mediated drug disposition (TMDD) conclusively demonstrated', 'saturation of PD-1 in systemic circulation at doses much lower than 200 mg Q3W. Second, a', 'PBPK analysis was conducted to predict tumor PD-1 saturation over a wide range of tumor', 'penetration and PD-1 expression. This evaluation concluded that pembrolizumab at 200 mg', 'Q3W achieves full PD-1 saturation in both blood and tumor.', 'Finally, population PK analysis of pembrolizumab, which characterized the influence of body', 'weight and other participant covariates on exposure, has shown that the fixed-dosing provides', 'similar control of PK variability as weight-based dosing, with considerable overlap in the', 'distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose. Supported', 'by these PK characteristics, and given that fixed-dose has advantages of reduced dosing', 'complexity and reduced potential of dosing errors, the 200 mg Q3W fixed-dose was selected for', 'evaluation across all pembrolizumab protocols.', 'Recently, pembrolizumab 200 mg intravenously every three weeks in combination with lenvatinib', '20 mg orally once daily is approved by FDA for patients with advanced endometrial carcinoma that', 'is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have', 'disease progression following prior systemic therapy and are not candidates for curative surgery or', 'radiation [13].', '4.2.3', 'Rationale for Enppoints', '4.2.3.1 Efficacy Enppoints', 'Primary endpoint:', 'Objective response rate was chosen as the primary endpoint to allow us to assess the proportion', 'of patients with a reduction in overall tumor burden from baseline after 12 weeks of treatment', 'with neoadjuvant lenvatinib and pembrolizumab. This endpoint can be assessed after just 12', 'weeks of treatment and has immediate implications on surgical planning and potentially long-', 'term effects on DFS and OS.', 'Page 9', 'Version Date: 05/08/2020']\n\n###\n\n", "completion": "END"}